BFRI

Insider Trades

Name	Value	Action	Price	Current Price
Biofrontera AGDirector, 10 Percent Owner: $23k shares BuySep 16, 2025 $0.0006 --

News

seekingalpha.comBiofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcriptseekingalpha.comJun 11

globenewswire.comBiofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026globenewswire.comMay 21

zacks.comBiofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimateszacks.comMay 14

globenewswire.comBiofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Updateglobenewswire.comMay 14

Trade BFRI

About Biofrontera Inc.

Biofrontera Inc. is a biopharmaceutical enterprise dedicated to the marketing and distribution of pharmaceutical products within the United States, specifically targeting various dermatological conditions. The company's portfolio includes Ameluz, a prescribed medication designed for photodynamic therapy. This treatment, utilized in conjunction with its licensor's RhodoLED lamp series, addresses mild-to-moderate actinic keratosis on the face and scalp through both localized (lesion-directed) and broader area (field-directed) applications. Furthermore, Biofrontera offers Xepi, a prescription cream indicated for the treatment of impetigo. The firm was founded in 2015 and operates from its headquarters located in Woburn, Massachusetts.

CEO: Hermann Luebbert
IPO Date: Oct 29, 2021

Market Data

Open: $1.01
High: $1.01
Low: $0.98
Volume: 206.3K
Avg Volume: 188.5K
52W High: $1.19
52W Low: $0.555

Valuation

Market Cap: $13M
Enterprise Value: $14M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-13M
Revenue: $42M
Net Income: $-11M
Cash: $6.4M
Debt: $6.2M

Events

EarningsAug 12

EPS est. -0.105